KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accumulated Depreciation (2018 - 2023)

Vir Biotechnology's Accumulated Depreciation history spans 5 years, with the latest figure at $18.9 million for Q3 2022.

  • For Q3 2022, Accumulated Depreciation changed N/A year-over-year to $18.9 million; the TTM value through Sep 2022 reached $18.9 million, changed N/A, while the annual FY2021 figure was $14.5 million, 56.98% up from the prior year.
  • Accumulated Depreciation for Q3 2022 was $18.9 million at Vir Biotechnology, up from $14.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $18.9 million in Q3 2022 and bottomed at $1.7 million in Q4 2018.
  • The 5-year median for Accumulated Depreciation is $7.5 million (2020), against an average of $8.5 million.
  • The largest annual shift saw Accumulated Depreciation surged 181.59% in 2019 before it surged 56.98% in 2021.
  • A 5-year view of Accumulated Depreciation shows it stood at $1.7 million in 2018, then skyrocketed by 181.59% to $4.8 million in 2019, then skyrocketed by 91.06% to $9.2 million in 2020, then soared by 56.98% to $14.5 million in 2021, then surged by 30.58% to $18.9 million in 2022.
  • Per Business Quant, the three most recent readings for VIR's Accumulated Depreciation are $18.9 million (Q3 2022), $14.5 million (Q4 2021), and $9.2 million (Q4 2020).